Corrigendum

Corrigendum to “Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme” [Int. J. Infect. Dis. 97 (2020) 182–189]

Anai García Fariñasa,*, Nivaldo Linares-Péreza, Andrew Clarkb, Maria Eugenia Toledo-Románc, Nathalie El Omeiri, Martha C. Marrero Araújo, Isabel Pilar González Luisa, Gilda Toraño Peraza, Alicia Reyes Jiménez, Lena López Ambrón, The Cuban Pneumococcal Vaccine Working Group

*Finlay Vaccine Institute, Havana, Cuba
bLondon School of Hygiene & Tropical Medicine, London, United Kingdom
cInstitute of Tropical Medicine Pedro Kouri, Havana, Cuba
dPan American Health Organization, Washington, D.C., USA
eNational School of Public Health, Havana, Cuba
fMinistry of Public Health, Havana, Cuba

The authors regret that the Methods section has error in the formula. Corrections follow.

In the Modelling approach section . . .
For a given week (w) of age, the number of disease events Dw was calculated as:

\[ D_w = P \times S \times w \times (1 - V_w) \]

where: \( P \times S \times w \) is the number of disease events in week w of age; \( V_w \) is the effect of vaccination in week w of age; P is the number of person-years lived between birth and age 5.0 years in the birth cohort evaluated; S is the streptococcus pneumoniae (pneumococcal) disease event rate per 100,000 per year among children younger than 5 years before the introduction of vaccination; and \( A_w \) is the proportion of pneumococcal disease events in children younger than 5 years in week w of age.

In the Pneumococcal disease burden inputs section . . .
For each birth cohort, estimates of person-years lived between birth and age 5.0 years (P) were based on United Nations demographic projections (https://population.un.org/wpp/). We estimated disease event rates (S) separately for pneumococcal acute otitis media (AOM), non-severe pneumococcal pneumonia, severe pneumococcal pneumonia, pneumococcal meningitis and other non-pneumonia/non-meningitis pneumococcal disease (NPNM) (Table 1).

The authors would like to apologise for any inconvenience caused.

DOI of original article: http://dx.doi.org/10.1016/j.ijid.2020.05.078

* Corresponding author.
E-mail address: agfarinas@finlay.edu.cu (A.G. Fariñas).

http://dx.doi.org/10.1016/j.ijid.2020.08.072
1201-9712/© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).